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Abstract 1 
 2 
Diagnosing pulmonary tuberculosis (TB) may be delayed until culture results become available. 3 
 4 
We ascertained the accuracy of a stepwise diagnostic algorithm for the rapid diagnosis of 5 
pulmonary TB by GeneXpert from sputum and/or bronchoalveolar-lavage (BAL) followed by a M. 6 
tuberculosis-specific BAL-enzyme-linked immunospot (ELISpot) assay in patients with a suspected 7 
diagnosis of pulmonary TB at a clinical referral center in Germany. 8 
 9 
Among 166 patients with a presumptive diagnosis of pulmonary TB, 81 cases were confirmed by 10 
M. tuberculosis culture from sputum and/or BAL. In 66/81 (81.5%) cases patients had initially M. 11 
tuberculosis detected by GeneXpert from sputum. In addition, 6/81 (7.4%) were diagnosed by 12 
GeneXpert on BAL-fluid (together 72/81 (88.9%) patients). Out of the remaining 9 patients with 13 
negative GeneXpert results from sputum and BAL, BAL-ELISpot identified 8 patients with culture 14 
confirmed TB correctly (median time to culture positivity 26 days). At a cut-off of >4000 ESAT-6 or 15 
CFP-10-specific Interferon- producing lymphocytes per 1,000,0000 lymphocytes the specificity of 16 
the BAL-ELISpot for active TB was 97%. 17 
 18 
In low incidence countries of TB, nearly all patients with active pulmonary TB can be identified 19 
within the first few days of clinical presentation using a stepwise strategy with GeneXpert and BAL-20 
Elispot. 21 
 22 
 23 
 24 
Introduction 1 
 2 
According to the World Health Organization (WHO), 10.4 million new cases of tuberculosis (TB) 3 
occurred worldwide in 2016 [1]. Early diagnosis of pulmonary TB is crucial to avoid transmission 4 
of Mycobacterium tuberculosis. M. tuberculosis culture remains the gold standard for TB diagnosis, 5 
but it takes 2-5 weeks on average until culture results become available [2-3]. The detection of 6 
acid-fast bacilli (AFB) by sputum smear microscopy is a widely used, inexpensive screening test in 7 
patients with presumptive diagnosis of pulmonary TB. However, less than 50% of all notified cases 8 
are sputum smear positive [4]. Furthermore, microscopy does not distinguish M. tuberculosis from 9 
other mycobacterial species. Nucleic acid amplification techniques such as GeneXpert (Xpert 10 
MTB/RIF, Cepheid, Sunnyvale, CA; USA) have a short time-to-result of less than two hours and are 11 
highly sensitive and specific for the detection of M. tuberculosis DNA on AFB-smear-positive 12 
samples. However, the sensitivity of GeneXpert for the diagnosis of pulmonary TB decreases to 13 
less than 70% for smear negative cases [5]. Thus approximately 15% of adult patients with 14 
pulmonary TB remain undetected when initially investigated by GeneXpert. 15 
 16 
Following the contact with antigen-presenting cells, M. tuberculosis-specific T-cells clonally 17 
expand in regional lymph nodes and migrate to the site of the infection where they differentiate 18 
into effector T-cells [6-8]. After loss of special phenotypical T-cell surface markers, these cell 19 
populations are probably unable to re-enter the blood stream and get enriched at the site of 20 
disease [9,10]. In contrast to detection of M. tuberculosis-specific effector T-cells in peripheral 21 
blood, detection of M. tuberculosis-specific effector T-cells by interferon- release assay (IGRA) at 22 
the site of the infection has a high diagnostic accuracy for active TB even when AFBs and M. 23 
tuberculosis-DNA are not detectable from local samples like bronchoalveolar-lavage (BAL) [11-15], 24 
pleural fluid [16,17], pericardial fluid [18], cerebrospinal fluid [19] or ascites [20]. Enzyme-linked 25 
immunospot (ELISpot) test results are available within 24 hours. 26 
 27 
In order to ascertain the diagnostic accuracy of the stepwise testing of sputum or BAL by 28 
GeneXpert followed M. tuberculosis-specific BAL-ELISpot testing for the rapid diagnosis of active 29 
pulmonary TB, we prospectively enrolled patients with the presumptive diagnosis of pulmonary 30 
TB at a clinical TB referral center in Germany. 31 
 32 
Methods 1 
 2 
Study participants 3 
We performed a prospective analysis of all patients (age ≥ 17 years) admitted to the Medical Clinic 4 
of the Research Center Borstel, Germany, between November 2011 and June 2016 presenting with 5 
symptoms and / or chest X-ray suggestive of pulmonary TB. Patients who had received treatment 6 
for TB within the last two years prior to admission, and patients with extra-pulmonary TB were 7 
excluded from the study. As the initial diagnosis sputum smear microscopy and/ or GeneXpert was 8 
performed on up to three sputum samples. In the absence of detectable acid-fast bacilli in smear 9 
and /or negative M. tuberculosis-specific nucleic acid tests on sputum, bronchoscopy with BAL was 10 
performed according to national guidelines [21]. Pooled BAL was divided into two aliquots, one 11 
each for ELISpot, the other aliquot was sent for BAL microscopy, GeneXpert and culture to the 12 
National Reference Center for Mycobacteria in Borstel (Germany). The study flow diagram is 13 
shown in figure 1. 14 
 15 
The study was approved by the Ethics Committee of the University of Lübeck (14-031A). Reporting 16 
follows the STARD criteria [22]. 17 
 18 
GeneXpert  19 
GeneXpert was performed on sputum and BAL according to manufacturer’s guidelines [23] at the 20 
National Reference Center for Mycobacteria in Borstel, Germany.  21 
 22 
M. tuberculosis-specific ELISpot Test 23 
M. tuberculosis-specific ELISpot was performed on PBMC and cells from bronchoalveolar lavage 24 
(BALC) as described previously [12]. Results of M. tuberculosis-specific ELISpot were considered 25 
positive if more than five spot-forming cells (SFCs) were observed in the ESAT-6 or the CFP-10 well, 26 
after subtracting the number of SFCs in the negative control well, and if the total number of SFCs 27 
in the ESAT-6 or CFP-10 well was at least twice the number of SFCs in the negative control well. 28 
The results were considered negative if they did not meet the definition for a positive result and 29 
if the number of SFCs in the positive control (anti-CD3, clone X35, 10 ng/ml; Beckman Coulter, 30 
Krefeld, Germany) was >20 SFCs after subtracting the number of SFCs in the negative control well 31 
and if it had at least twice the number of SFCs of the negative control well. Indeterminate results 32 
were defined as meeting neither the criteria for a positive, nor a negative test result. Due to limited 1 
number of cells in BALs, some ELISpot tests were performed with less than 250,000 cells per well, 2 
these results were normalized for 250,000 cells per well.  3 
 4 
Defining the lymphocyte population by flow cytometry analysis 5 
To adjust for the different percentages of lymphocytes in blood and lavage, 500.000 PBMCs or 6 
BALCs were acquired on a FACS calibur (BD Bioscience, Heidelberg, Germany). The respective 7 
percentage of lymphocytes out of the population of PBMC or BALC was used to extrapolate SFCs 8 
per 250,000 cells per well to 1,000,000 lymphocytes in blood or BAL specimen [12]. Recruitment 9 
of M. tuberculosis-specific lymphocytes to the lungs was calculated by dividing the number of SFC 10 
/ 1,000,000 lymphocytes in BALC by the number of SFC / 1,000,000 lymphocytes in the peripheral 11 
blood. As previously described, in case the denominator had zero SFC, a value of 0.1 was assigned 12 
as published earlier [12,24]. 13 
 14 
Statistical Analysis 15 
Statistical analysis was performed using STATA version 14 (Stata-Corp., TX, USA) and CATmaker 16 
version 1.1 (Center for Evidence-Based Medicine, Oxford, UK). The Mann-Whitney U test was used 17 
to compare groups of continuous variables. The cut-offs were selected using receiver operating 18 
characteristic analysis. The significance level was set at α=0.05.  19 
 20 
Results 21 
From 01.11.2011 to 30.06.2016, 412 patients with a presumptive or confirmed diagnosis of TB 22 
were admitted to the Medical Clinic of the Research Center Borstel, Germany. Of these, 196 23 
patients had already a confirmed diagnosis of pulmonary TB. Another 50 patients were diagnosed 24 
with extrapulmonary TB. These patients were excluded. Of the remaining 166 individuals, who 25 
were admitted with presumptive pulmonary TB, 66 patients had a microbiological confirmation of 26 
the initial diagnosis made by a positive GeneXpert test result on sputum. The remaining 100 27 
individuals, in whom the diagnosis of TB could not be confirmed by sputum smear microscopy and 28 
sputum GeneXpert, but where pulmonary TB was still part of the differential diagnosis, underwent 29 
bronchoscopy with BAL. 30 
The median age of these 100 patients was 52.0 years (IQR 35.5-63.0), sixty-one (61%) were male.  1 
One patient with culture-confirmed tuberculosis and one patient without tuberculosis were 2 
tested HIV-positive. 3 
Fifteen/100 patients had culture-confirmed TB. Six patients with culture-confirmed TB (40%) had 4 
a rapid diagnosis of TB by a positive BAL GeneXpert result (of whom two also had detectable 5 
acid-fast bacilli) on BAL microscopy, four without detectable AFBs in BAL). Thus, there were 6 
9/100 (9%) patients with negative test results on sputum and BAL by microscopy and GeneXpert 7 
that had culture confirmed diagnosis of TB with a median time to culture positivity of 26 days 8 
(IQR 16.5 -34.5). Patient characteristics are shown in table 1.  9 
 10 
Among the 100 patients who underwent bronchoscopy, four were diagnosed with non-11 
tuberculous mycobacterial (NTM) pulmonary infections. Two patients had the evidence of AFBs in 12 
BAL and the GeneXpert did not detect M. tuberculosis, the mycobacterial species identified from 13 
culture in these patients were M. avium and M. simiae. Two individuals with negative results on 14 
BAL microscopy and GeneXpert had a positive culture from BAL for M. xenopi and M. kansasii. 15 
Samples from the remainder 81 patients did not show mycobacterial growth. Patient 16 
characteristics and details on the final diagnosis of the patients, who underwent bronchoscopy 17 
but were ultimately diagnosed as not-having pulmonary tuberculosis, are shown in the supporting 18 
information table 1.   19 
 20 
PBMC- and BALC-ELISpot results 21 
Among 100 patients with a presumptive diagnosis of pulmonary TB, one had an indeterminate test 22 
result in PBMCs. In 1/100 (1%) there was failure of the positive control in the PBMC-ELISpot. In 23 
5/100 (5%) the BALC-ELISpot was indeterminate: two had failure of the negative control and three 24 
had failure of the positive control. Using the manufacturer´s definition of a positive test result, 25 
among the patients with valid test results PBMC- and BALC-ELISpot were positive in 62/99 (62.6%) 26 
and 40/95 (42.1%) individuals, respectively. Active TB could be excluded in 34/62 (54.8%) 27 
individuals with a positive PBMC-ELISpot and 25/40 (62.5%) with a positive BALC-ELISpot. Out of 28 
15 patients with culture-confirmed pulmonary TB, PBMC-ELISpot was positive in 14/15 (93.3%) 29 
and negative in 1/15 (6.7%). BALC-ELISpot was positive in 15/15 (100%).  30 
 31 
For patients with culture-confirmed pulmonary TB, PBMC-ELISpot had a sensitivity of 93% (95%CI 1 
81-100%) and a specificity of 50% (95%CI 38-62%), while the BALC-ELISpot had a sensitivity of 2 
100% and a specificity of 77% (95%CI 67-87%) when the manufacturer´s definition of a positive 3 
and negative  test result on PBMCs was used. 4 
 5 
Table 2 shows all individual test results for the nine culture-confirmed pulmonary TB patients with 6 
negative AFB and negative GeneXpert results in BAL. The respective numbers of positive or 7 
negative paired PBMC- and BALC-ELISpot results in patients with culture-confirmed pulmonary TB 8 
and patients without TB are given in supporting information figure S1. 9 
 10 
Concentration of antigen-specific cells at the site of infection  11 
In patients with culture confirmed pulmonary TB, the median antigen-specific SFC was 25 SFC (IQR 12 
6.3-210) per 250,000 PBMC for ESAT-6 and 53.8 (IQR 22.5-177) per 250,000 PBMC for CFP-10. 13 
BALC-ELISpot median was elevated to 295 SFC (IQR 52.5-489) per 250,000 BALC for ESAT-6 and 14 
160 SFC (IQR 61-453) per 250,000 BALC for CFP-10. In contrast, patients without TB had a median 15 
of 3.8 SFC (IQR 0.1-17.5) per 250,000 PBMC for ESAT-6 and 4.3 SFC (IQR 0.1-16.9) per 250,000 16 
PBMC for CFP-10 and in the BAL the median for both ESAT-6 and CFP-10 was low with 0 SFC per 17 
250,000 BALC. Figure 2 and supporting information figure S1 show the number of antigen specific 18 
cells in 250,000 PBMC and BALC in patients with culture-confirmed pulmonary TB but 19 
undetectable AFBs on microscopy and negative GeneXpert result compared to patients in whom 20 
TB had been excluded.  21 
 22 
Concentration of antigen-specific lymphocytes at the site of infection  23 
To account for the different percentages of lymphocytes between individuals, SFC results in PBMC 24 
and BAL were normalized for 1,000,000 lymphocytes. In patients with culture-confirmed 25 
pulmonary TB, the median of antigen-specific lymphocytes per 1,000,000 in peripheral blood was 26 
121 SFC (IQR 43.9-1228.8) for ESAT-6 and 270 SFC (IQR 109.8-1363.8) for CFP-10, while in the BAL 27 
the median was 6370 SFC (IQR 4595.2-14541.7) for ESAT-6 and 6598.5 SFC (IQR 3857.7-13503.7) 28 
for CFP-10. By comparison, patients with other diagnosis than TB had a median of 25.5 SFC (IQR 29 
0.8-99.9) ESAT-6 and 27 SFC (IQR 0.7-93.8) CFP-10-specific lymphocytes in peripheral blood, while 30 
in the BAL they had a median of 0 SFC (IQR 0-0) of ESAT-6 and 0 SFC (IQR 0-0) of CFP-10 specific 31 
lymphocytes per 1,000,000 lymphocytes. Figure 3 and supporting information figure S2 shows 32 
the number of antigen specific lymphocytes per 1,000,000 lymphocytes in PBMCs and BALCs in 1 
patients with culture-confirmed pulmonary TB but negative AFB microscopy / negative GeneXpert 2 
result compared to patients without TB. 3 
 4 
Differentiation of active TB from non-TB 5 
To improve the discrimination between patients without TB and those with culture–confirmed 6 
pulmonary TB but undetectable AFB on microscopy and negative GeneXpert result in BAL, 7 
different cut-offs were investigated. A cut-off of 50 SFC of ESAT-6 or 50 SFC of CFP-10 specific cells 8 
from 250,000 BALC provides a sensitivity of 100% and a specificity of 91% (IQR 84-98%). 9 
Considering the proportion of lymphocytes, a cut-off of at least 4000 antigen-specific lymphocytes 10 
for either ESAT-6 or CFP-10 per 1,000,000 BAL-lymphocytes had a sensitivity of 89% (IQR 68-100) 11 
and a specificity of 97% (IQR 93-100%). To account for the different percentages of lymphocytes 12 
in BAL and peripheral blood a recruitment factor was defined as the ratio of SFC in BALC divided 13 
by the SFC in PBMC and multiplied with the lymphocyte factor (% of lymphocytes in PBMC divided 14 
by the % lymphocytes in BALC). A recruitment factor of at least 6 for ESAT-6 or CFP-10 had a 15 
sensitivity of 67% (IQR 36-97%) and a specificity of 83% (IQR 74-92%).  16 
 17 
The area under the ROC curve to differentiate patients without TB from the subgroup of patients 18 
with culture-confirmed pulmonary TB but undetectable AFBs on microscopy and negative 19 
GeneXpert result was 0.968 for ESAT-6 and 0.985 for CFP-10 specific BALCs, while the area under 20 
the ROC curve for PBMC was 0.760 for ESAT-6 and 0.841 for CFP-10. When evaluating the 21 
1,000,000 lymphocytes from the BALC only, the area under the ROC curve was 0.973 for ESAT-6 22 
and 0.978 for CFP-10. 23 
 24 
When applying these cut-offs for BAL-lymphocytes (instead of the ones provided by the 25 
manufacturer for the use on PBMCs) to the entire group of patients with culture-confirmed 26 
pulmonary TB, a number of at least 50 antigen-specific BALCs had a sensitivity of 100% (95% CI: 27 
100 -100%) and a specificity of 91% (95% CI: 84-98%), while a number of at least 4000 antigen-28 
specific BAL-lymphocytes per 1,000,000 lymphocytes had a sensitivity of 89% (95% CI: 68-100) and 29 
a specificity of 97% (95% CI: 93-100%). A recruitment factor of at least 6 had a sensitivity of 73% 30 
(95% CI:  51-96%) and a specificity of 83% (95% CI:  74-92%).  31 
 32 
Table 3 shows the performance of ELISpot on BALCs using these different cut-offs. Supporting 1 
information figure S3 gives the graphs of the respective area under ROC curves.  2 
 3 
In summary, among 166 patients, who were admitted with a presumptive diagnosis of pulmonary 4 
TB, the diagnosis was confirmed by M. tuberculosis culture in 81 patients (48.8%). 66/81 (81.5%) 5 
had initially a positive GeneXpert result from sputum and in addition 6/81 (7.4%) were diagnosed 6 
by BAL GeneXpert (together 72/81; 88.9%). In 8 out of 9/81 (88.8%) patients with negative results 7 
on sputum and BAL by microscopy and GeneXpert, BAL-ELISpot identified patients with culture 8 
confirmed TB correctly with a specificity of 97%.  9 
With a stepwise analysis of GeneXpert (2h) and BAL-ELISpot only for patients with a negative BAL-10 
GeneXpert test result, the combined sensitivity and specificity for a rapid diagnosis of pulmonary 11 
TB was 98.8% and 97.6%, respectively (table 4). 12 
 13 
Discussion 14 
 15 
We evaluated the accuracy of a stepwise approach consisting of an initial molecular test, the 16 
GeneXpert, followed by a M. tuberculosis-specific BAL-ELISpot for the diagnosis of pulmonary TB. 17 
Using BAL-GeneXpert and BAL-Elispot sequentially, the diagnostic accuracy for sputum-smear and 18 
GeneXpert-negative pulmonary TB was 97 %. The diagnosis became available within the first days 19 
of presentation to the hospital. 20 
 21 
GeneXpert has greatly improved the diagnosis of TB. If GeneXpert is performed on two different 22 
sputum samples, more than 90% of adult patients with pulmonary TB were being correctly 23 
identified by GeneXpert within the first days of presentation to a healthcare facility [25]. However, 24 
the sensitivity of GeneXpert is lower in sputum smear negative and in extrapulmonary TB [25,26]. 25 
If results from GeneXpert tests are negative, patients could remain undiagnosed for several weeks 26 
until culture results of M. tuberculosis cultures become available.  27 
 28 
M. tuberculosis-specific ELISpot performed on cells from the BAL is able to close this diagnostic 29 
gap. In the past decade several studies have shown that M. tuberculosis-specific ELISpot 30 
performed on specimens from the site of the disease e.g. BAL in pulmonary TB, pleural or 31 
pericardial effusion in TB pleurisy or TB pericarditis, respectively, ascites in TB peritonitis or 32 
cerebrospinal fluid in TB meningitis [27-30] can improve the case detection rate of TB in 1 
paucibacillary disease, but the added value of a stepwise approach of GeneXpert and ELISpot had 2 
not been investigated so far. 3 
 4 
In active TB, M. tuberculosis-specific lymphocytes are recruited from the blood into the disease-5 
affected organ [31,32]. Active disease is more likely with increasing concentration of M. 6 
tuberculosis-specific cells at the site of infection compared to peripheral blood [24]. Hofland et al. 7 
suggested a ratio between SFC in BAL divided by SFC in blood with a cut-off >1 [33]. However, one 8 
needs to consider, that lymphocytes predominate in peripheral blood, whereas their proportion 9 
in BAL is considerably lower [34]. These differences in percentages of lymphocytes in PBMC and 10 
BALC should be acknowledged individually by calculating a lymphocyte-depending recruitment 11 
factor of ESAT-6 and CFP 10 specific T-cells between blood and BALC or by normalizing the SFC per 12 
250.000 cells to 1,000,000 lymphocytes [11,24].   13 
 14 
Optimal result were obtained in this study with a cut-off of >4000 lymphocytes per 1,000,000 15 
lymphocytes in BAL. When applying this cut-off, patients with paucibacillary pulmonary TB could 16 
be identified with a sensitivity of 89% and a specificity of 97%. This cut-off provided an excellent 17 
negative predicted value of 98% and a high positive likelihood ratio of 28.9.  18 
 19 
Like most studies from low incidence countries, our study is limited by the sample size of patients 20 
with culture confirmed active TB and negative GeneXpert results from sputum and BAL. 21 
Performing BAL-ELISpot and flow cytometry is also substantially more labour-intensive and 22 
requires considerably more technician time than automated M. tuberculosis- specific nucleic acid 23 
amplification by GeneXpert. However, most patients who are suspected to have pulmonary TB in 24 
low-incidence countries of TB with sufficient economical resources will undergo bronchoscopy 25 
when results of sputum smear microscopy and sputum GeneXpert analysis are negative, also to 26 
exclude alternative diseases such as sarcoidosis, cryptogenic organizing pneumonia, lung cancer, 27 
and others. Furthermore, the results cannot be generalized to high burden countries, where 28 
repeated exposure to M. tuberculosis may alter BAL-ELISpot responses [14] and performance of 29 
the ELISpot would be challenging due to limited laboratory capacity.  30 
 31 
Due to the high sensitivity for pulmonary TB of GeneXpert performed on respiratory specimen, 1 
the performance of M. tuberculosis specific BAL-ELISpot can be limited to patients where the 2 
GeneXpert result from sputum and BAL are negative and when the differential diagnosis of active 3 
pulmonary TB is still to be considered.  4 
 5 
In conclusion, in low-incidence counties of TB, nearly all patients with active pulmonary TB can be 6 
identified within the first few days of clinical presentation by using a stepwise testing strategy with 7 
GeneXpert and BAL-Elispot. 8 
  9 
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Tables 1 
 2 
Table 1: Individual test results and patient characteristic of the nine patients with culture-3 
confirmed TB with undetectable acid-fast bacilli (AFB) in bronchoalveolar lavage (BAL) and 4 
negative GeneXpert results.  5 
MTB: Mycobacterium tuberculosis; ITR: indeterminate test result; PBMC: peripheral blood 6 
mononuclear cells; TPP: time to culture positivity of the first culture growing MTB, specimen was 7 
either sputum* or BAL#.  8 
 9 
No. Age Sex Country of origin 
MTB    
culture 
AFB 
BAL 
GeneXpert 
BAL 
PBMC 
ELISpot 
BALC              
ELISpot         TPP 
1 30 m Somalia + -  - + +                    17* 
2 31 m Ghana + - - + +                    31* 
3 69 m Germany + - ITR + +                    16# 
4 62 f Afghanistan + - - + +                    38# 
5 27 f Germany + - - + +                    21# 
6 43 m Germany + - - + +                    16* 
7 19 f Germany + - - + +                    28#         
8 48 m Russia + - - + +                    26# 
9 33 m Eritrea + - - + +                    39* 
 10 
 11 
 12 
  13 
Table 2: Individual ELISpot results and recruitment factor for the nine patients with culture-1 
confirmed tuberculosis with acid fast bacilli negative microscopy and negative GeneXpert result in 2 
BAL.  3 
PBMC: peripheral blood mononuclear cells, BALC: bronchoalveolar lavage cells, E: early secretory 4 
antigenic target (ESAT)-6, C: culture filtrate protein (CFP)-10, Ly: lymphocytes, Rec: recruitment 5 
factor = spot forming cells (SFC) in BALC divided by SFC in PBMC multiplied with percentage of 6 
lymphocytes in PBMC divided by percentage of lymphocytes in BAL.  7 
PBMC/BAL ESAT-6/ CFP-10 250cells: results are expressed per 250,000 mononuclear cells; 8 
PBMC/BAL ESAT-6/ CFP-10 1000Ly: results are expressed per 1,000,000 lymphocytes. 9 
 10 
 11 
 12 
 13 
 Age Sex PBMC 
ESAT-6 
250cells 
PBMC 
CFP-10 
250cells 
BALC 
ESAT-6 
250cells 
BALC 
CFP-10  
250cells 
PBMC 
ESAT-6 
1000Ly 
PBMC 
CFP-10 
1000Ly 
BALC  
ESAT-6 
1000Ly 
BALC  
CFP-10 
1000Ly 
Rec  
ESAT-6 
Rec  
CFP-10 
1 30 M 473 301 407 279 3300 2100 15654 10731 4.7 5.,1 
2 31 M 210 195 526 351 1761 1635 6370 4251 3.6 2.6 
3 69 M 291 64 450 621 1229 270 4780 6599 3.9 24.4 
4 62 F 6 6 546 479 44 44 12248 10734 279.2 244.7 
5 27 F 2,5 10 251 160 12 47 6058 3858 514.9 81.9 
6 43 M 25 23 295 349 122 110 18820 21930 145.3 199.8 
7 19 F 15 33 176 159 73 161 5949 5359 81.3 33.3 
8 48 M 20 29 52,5 50 113 162 4595 4376 40.8 27 
9 33 M 5 47 6 61 24 229 107 1085 4.4 4.7 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
 26 
 27 
 28 
 29 
 30 
  31 
Table 3: Performance of different cut-offs for M. tuberculosis -specific BALC-ELISpot for the diagnosis of active tuberculosis. 1 
CFP-10: culture filtrate protein-10, ESAT-6: early secretory antigenic target-6, BALC: bronchoalveolar lavage cells, BAL-Ly: bronchoalveolar lavage 2 
lymphocytes, Rec: recruitment factor = spot forming cells (SFC) in BALC divided by SFC in PBMC multiplied with percentage of lymphocytes in 3 
PBMC divided by percentage of lymphocytes in BALC, Ratio: ratio of SFC in BALC divided by SFC in PBMC, CI: confidence interval, PPV: positive 4 
predictive value, NPV: negative predictive value, CC: correctly classified, LR: likelihood ratio. 5 
The test performance was computed for the 100 individuals, who underwent bronchoscopy with BAL.  6 
 7 
 8 
 9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
  21 
Cut-off Sensitivity 
in % 
(95% CI) 
Specificity 
in % 
(95% CI) 
PPV 
in % 
(95% CI) 
NPV 
in % 
(95% CI) 
CC 
in % 
LR+ 
in % 
(95% CI) 
LR- 
in % 
(95% CI) 
False positive -> 
treated 
unnecessarily 
Area under 
the ROC 
curve 
CFP-10 or 
ESAT-6  
>50 BALC 
100 
(100-100) 
91 
(84-98) 
60 
(35-85) 
100 
(100-100) 
91.9 
10.8 
(5.1-23.2) 
na 6/100 (6%) 
ESAT: 0.968 
CFP: 0.985 
CFP-10 or 
ESAT-6  
>4000 BAL-Ly 
89 
(68-100) 
97 
(93-100) 
80 
(55-100) 
98 
(95-100) 
95.9 
28.9 
(7.2-115.3) 
0.1 
(0.02-0.7) 
2/100 (2%) 
ESAT: 0.973 
CFP: 0.978 
CFP-10 or 
ESAT-6  
Rec >6 
67 
(36-97) 
83 
(74-92) 
35 
(13-58) 
95 
(89-100) 
80.8 
3.9 
(1.9-7.9) 
0.4 
(0.2-1) 
11/100 (11%) 
ESAT: 0.879 
CFP: 0.910 
CFP-10 or 
ESAT-6  
Ratio >2 
78 
(51-100) 
84 
(75-93) 
41 
(18-65) 
96 
(92-100) 
83.6 
5 
(2.6-9.7) 
0.26 
(0.08-0.9) 
10/100 (10%) 
ESAT: 0.892 
CFP: 0.915 
Table 4: Performance of a combined approach of GeneXpert and BAL-ELISpot for the diagnosis of active tuberculosis.  1 
BAL-Ly: bronchoalveolar lavage lymphocytes, CI: confidence interval, PPV: positive predictive value, NPV: negative 2 
predictive value, CC: correctly classified, LR: likelihood ratio. 3 
Test performance of this stepwise approach of combined GeneXpert and ELISpot refers to 166 individuals (100 BAL, 66 sputum). 4 
 5 
 6 
 7 
 8 
Cut-off Sensitivity 
in % 
(95% CI) 
Specificity 
in % 
(95% CI) 
PPV 
in % 
(95% CI) 
NPV 
in % 
(95% CI) 
CC 
in % 
LR+ 
in % 
(95% CI) 
LR- 
in % 
(95% CI) 
False positive -> 
treated 
unnecessarily 
Combined 
GeneXpert 
and ELISpot 
>4000 BAL-Ly 
99  
(96-100) 
98 
(94-100) 
98 (94-
100) 
99 
(96-100) 
98.2 
42 
(10.7-165.2) 
0.01  
(0-0.1) 
2/166 (1.2%) 
Legends  1 
 2 
Figure 1: Study flow diagram. TB: tuberculosis, BAL: bronchoalveolar lavage, GeneXpert: 3 
GeneXpert MTB/RIF. MTB Culture: TB diagnosis was confirmed by growth of Mycobacterium 4 
tuberculosis.  5 
 6 
Figure 2: Number of spot forming cells (SFC) of early secretory antigenic target (ESAT)-6- and 7 
culture filtrate protein (CFP)-10–specific peripheral blood mononuclear cells (PBMC) and 8 
bronchoalveolar-lavage cells (BALC) cells per 250,000 cells in individuals where tuberculosis was 9 
excluded (non-TB) and in patients with culture-confirmed pulmonary tuberculosis (TB) with 10 
undetectable acid fast bacilli on microscopy and negative GeneXpert result. A suggested cut-off 11 
>50 SFC per 250,000 cells is depicted as dotted line.  12 
 13 
Figure 3: Number of early secretory antigenic target (ESAT)-6- and culture filtrate protein (CFP)-14 
10–specific spot forming cells per 1,000,000 lymphocytes in peripheral blood mononuclear cells 15 
(PBMC) and bronchoalveolar lavage cells (BALC) in individuals where tuberculosis was excluded 16 
(non-TB) and in patients with culture confirmed pulmonary tuberculosis (TB) with undetectable 17 
acid-fast bacilli on microscopy and negative GeneXpert. A suggested cut-off >4000 antigen-specific 18 
lymphoyctes per 1,000,000 lymphoyctes is depicted as dotted line.  19 
 20 
Supporting information Figure S1 21 
Comparison of spot forming cells (SFC) of early secretory antigenic target (ESAT)-6- and culture 22 
filtrate protein (CFP)-10–specific peripheral blood mononuclear cells (PBMC) and bronchoalveolar 23 
lavage mononuclear cells (BALC) in patients with culture-confirmed pulmonary tuberculosis (TB) 24 
with undetectable acid fast bacilli on microscopy and negative GeneXpert result (upper row) and 25 
patients with other diagnoses after exclusion of TB (non-TB) (bottom row) by enzyme-linked 26 
immunospot (ELISpot). 27 
 28 
Supporting information Figure S2: Comparison of spot forming cells (SFC) of early secretory 29 
antigenic target (ESAT)-6- and culture filtrate protein (CFP)-10–specific lymphocytes per 30 
1,000,0000 lymphocytes from peripheral blood (Blood-Ly) or and bronchoalveolar lavage (BAL-Ly) 31 
in patients with culture-confirmed pulmonary tuberculosis (TB) and undetectable acid-fast bacilli 32 
on microscopy and negative GeneXpert MT/B/RIF result (upper row) and patients with other 1 
diagnoses after exclusion of TB (non-TB) (bottom row) by enzyme-linked immunospot (ELISpot). 2 
 3 
Supporting information Figure S3: Area under the ROC curve to differentiate patients without 4 
tuberculosis from patients with culture-confirmed pulmonary tuberculosis for culture filtrate 5 
protein (CFP)-10-specific bronchoalveolar lavage cells (BALC). The recruitment factor (Rec) was 6 
calculated as spot forming cells (SFC) in BALC divided by SFC in peripheral blood mononuclear 7 
cells (PBMC) multiplied with percentage of lymphocytes in PBMC divided by percentage of 8 
lymphocytes in BALC. The ratio (Ratio) was calculated as SFC in BALC divided by SFC in PBMC. 9 
Results are expressed per 250,000 BALC (250 cells) or 1,000,000 BAL-lymphocytes (1000 Ly). 10 
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 13 
 14 
